Todd Sherer

Todd Sherer

UNVERIFIED PROFILE

Are you Todd Sherer?   Register this Author

Register author
Todd Sherer

Todd Sherer

Publications by authors named "Todd Sherer"

Are you Todd Sherer?   Register this Author

46Publications

600Reads

41Profile Views

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Neurology 2019 Feb;92(7):329-337

From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology & Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson & Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología "José María Ramos Mejía" y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382364PMC
February 2019

The Emerging Evidence of the Parkinson Pandemic.

J Parkinsons Dis 2018 ;8(s1):S3-S8

Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JPD-181474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311367PMC
January 2018

Parkinson's disease is ready for precision medicine.

Per Med 2016 Sep 9;13(5):405-407. Epub 2016 Aug 9.

The Michael J Fox Foundation for Parkinson's Research, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pme-2016-0052DOI Listing
September 2016

Nilotinib - Differentiating the Hope from the Hype.

J Parkinsons Dis 2016 07;6(3):519-22

Michael J Fox Foundation for Parkinson's Research, New York, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044778PMC
http://dx.doi.org/10.3233/JPD-160904DOI Listing
July 2016

Neuroscience Training for the 21st Century.

Neuron 2016 06;90(5):917-26

National Science Foundation, Arlington, VA 22230, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuron.2016.05.030DOI Listing
June 2016

Use of an online portal to facilitate clinical trial recruitment: a preliminary analysis of Fox Trial Finder.

J Parkinsons Dis 2015 ;5(1):55-66

The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JPD-140522DOI Listing
November 2015

MORE THAN MONEY: THE EXPONENTIAL IMPACT OF ACADEMIC TECHNOLOGY TRANSFER.

Technol Innov 2014 Nov;16(1):75-84

University of South Florida, Tampa, FL, USA ; National Academy of Inventors, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3727/194982414X13971392823479DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104711PMC
November 2014

The future of research in Parkinson disease.

JAMA Neurol 2014 Nov;71(11):1351-2

Michael J. Fox Foundation for Parkinson's Research, New York, New York.

View Article

Download full-text PDF

Source
http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaneurol.2014.1717DOI Listing
November 2014

Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.

Neuron 2014 Nov 5;84(3):554-63. Epub 2014 Nov 5.

The Michael J. Fox Foundation for Parkinson's Research, P.O. Box 4777, New York, NY 10163, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuron.2014.10.027DOI Listing
November 2014

Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.

Mov Disord 2014 May 7;29(6):772-9. Epub 2014 Mar 7.

Motac Neuroscience Ltd, Manchester, United Kingdom; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25859DOI Listing
May 2014

Money without collaboration won't bring cures.

Authors:
Todd B Sherer

Nat Med 2013 Feb;19(2):127

The Michael J. Fox Foundation for Parkinson's Research in New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0213-127DOI Listing
February 2013

Overcoming obstacles in Parkinson's disease.

Mov Disord 2012 Nov 31;27(13):1606-11. Epub 2012 Oct 31.

The Michael J. Fox Foundation for Parkinson's Research, New York, New York 10163-4777, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25260DOI Listing
November 2012

Biomarkers for Parkinson's disease.

Authors:
Todd B Sherer

Sci Transl Med 2011 Apr;3(79):79ps14

The Michael J. Fox Foundation for Parkinson's Research, New York, NY 10004, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3002488DOI Listing
April 2011

Biomarkers in Parkinson's disease: a funder's perspective.

Biomark Med 2010 Oct;4(5):723-9

Michael J Fox Foundation for Parkinson's Research, 90 Broad Street, New York, NY 07030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/bmm.10.89DOI Listing
October 2010

Funding of Parkinson research from industry and US federal and foundation sources.

Mov Disord 2009 Apr;24(5):731-7

Department of Neurology, University of Rochester Medical Center, Rochester, New York 14620, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.22446DOI Listing
April 2009

Special focus section: gene therapy for Parkinson's disease.

Exp Neurol 2008 Jan 18;209(1):28-9. Epub 2007 Sep 18.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2007.09.006DOI Listing
January 2008

Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease.

J Neurochem 2007 Mar 4;100(6):1469-79. Epub 2007 Jan 4.

Center for Neurodegenerative Disease, Rollins School of Public Health, Atlanta, Georgia 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1471-4159.2006.04333.xDOI Listing
March 2007

Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Toxicol Sci 2007 Jan 12;95(1):196-204. Epub 2006 Oct 12.

Department of Environmental and Occupational Medicine, University of Medicine and Dentistry, New Jersey/Robert Wood Johnson Medical School and Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey 08854, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/toxsci/kfl133DOI Listing
January 2007

Crossroads in GDNF therapy for Parkinson's disease.

Mov Disord 2006 Feb;21(2):136-41

Michael J. Fox Foundation for Parkinson's Research, New York, New York 10005, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.20861DOI Listing
February 2006

Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication.

J Biol Chem 2005 Dec 21;280(51):42026-35. Epub 2005 Oct 21.

Carolinas Neuromuscular/ALS-MDA Center, Carolinas Medical Center, Charlotte, North Carolina 28203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M508628200DOI Listing
December 2005

Paraquat neurotoxicity is distinct from that of MPTP and rotenone.

Toxicol Sci 2005 Nov 1;88(1):193-201. Epub 2005 Sep 1.

Center for Neurodegenerative Disease, School of Medicine and Department of Environmental and Occupational Health, Rollins School of Public Health, Emory University, Atlanta, Georgia 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/toxsci/kfi304DOI Listing
November 2005

Oxidative damage in Parkinson's disease.

Antioxid Redox Signal 2005 May-Jun;7(5-6):627-9

The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/ars.2005.7.627DOI Listing
September 2005

Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.

Brain Res Mol Brain Res 2005 Mar 6;134(1):109-18. Epub 2005 Jan 6.

Center for Neurodegenerative Disease, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0169328X0400592
Publisher Site
http://dx.doi.org/10.1016/j.molbrainres.2004.11.007DOI Listing
March 2005

Ubiquitin-proteasome system and Parkinson's diseases.

Exp Neurol 2005 Feb;191 Suppl 1:S17-27

Center for Neurodegenerative Disease, Department of Neurology, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2004.08.021DOI Listing
February 2005

Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.

Chem Res Toxicol 2004 Nov;17(11):1540-8

Environmental Chemistry and Toxicology Laboratory, Department of Environmental Science, Policy and Management, University of California, Berkeley, California 94720-3112, USA.

View Article

Download full-text PDF

Source
http://www.researchgate.net/profile/Georgia_Taylor2/publicat
Web Search
http://dx.doi.org/10.1021/tx049867rDOI Listing
November 2004

Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease.

Exp Neurol 2004 May;187(1):76-85

Department of Neurology and the Center for Neurodegenerative Disease, Emory University, Atlanta GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2003.12.012DOI Listing
May 2004

Mechanism of toxicity in rotenone models of Parkinson's disease.

J Neurosci 2003 Nov;23(34):10756-64

Center for Neurodegenerative Disease, Emory University, Atlanta, Georgia 30322, USA.

View Article

Download full-text PDF

Source
November 2003

The rotenone model of Parkinson's disease: genes, environment and mitochondria.

Parkinsonism Relat Disord 2003 Aug;9 Suppl 2:S59-64

Center for Neurodegenerative Disease, Emory University, 615 Michael Street, Room 505M, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
August 2003

Selective microglial activation in the rat rotenone model of Parkinson's disease.

Neurosci Lett 2003 May;341(2):87-90

Center for Neurodegenerative Disease, Emory University, 30322, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
May 2003

Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.

Exp Neurol 2003 Jan;179(1):9-16

Center for Neurodegenerative Disease, Department of Neurology, Emory University, Atlanta, GA 30032, USA.

View Article

Download full-text PDF

Source
January 2003

Mechanistic approaches to Parkinson's disease pathogenesis.

Brain Pathol 2002 Oct;12(4):499-510

Center for Neurodegenerative Disease and Department of Neurology, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
October 2002

An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

J Neurosci 2002 Aug;22(16):7006-15

Center for Neurodegenerative Disease and Department of Neurology, Emory University, Atlanta, Georgia 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/20026721DOI Listing
August 2002

Environment, mitochondria, and Parkinson's disease.

Neuroscientist 2002 Jun;8(3):192-7

Department of Neurology, Emory University, Atlanta, Georgia 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1073858402008003004DOI Listing
June 2002

Animal models of Parkinson's disease.

Bioessays 2002 Apr;24(4):308-18

Department of Neurology, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bies.10067DOI Listing
April 2002